IDEXX Laboratories revenue and financials
$515.41Change from previous close: −2.21%Absolute change: −$11.66
In the fiscal year ended December 2025, IDEXX Laboratories reported revenue of $4.3B (+10.42% year over year). Net income was $1.06B, a net margin of 24.6%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +10.42%
- 2025 vs 2024
- Net income growth
- +19.33%
- 2025 vs 2024
- Net margin
- 24.6%
- 2024: 22.8%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1,182 | 929 | 907 | 543 | 756 | 648 | 459 | 400 | 373 | 339 |
| Depreciation and amortization | 145 | 130 | 115 | 112 | 105 | 96.0 | 88.0 | 83.2 | 83.1 | 78.2 |
| Capital expenditure | -125 | -121 | -134 | -149 | -120 | -107 | -155 | -116 | -74.4 | -64.8 |
| Investing cash flow | -136 | -207 | -125 | -195 | -293 | — | — | — | — | — |
| Financing cash flow | -1,165 | -878 | -442 | -371 | -697 | — | — | — | — | — |
| Share repurchases | -1,217 | -837 | -71.9 | -820 | -747 | -183 | -302 | -369 | -283 | -304 |
| Debt issued | 398 | 0.0 | 0.0 | 506 | 73.5 | — | — | — | — | — |
| Debt repaid | -428 | -75.0 | -404 | -75.0 | -50.0 | — | — | — | — | — |
| Effect of exchange rates | 11.2 | -9.5 | 2.1 | -8.6 | -4.6 | — | — | — | — | — |
| Net change in cash | -108 | -166 | 341 | -31.9 | -239 | — | — | — | — | — |
| Free cash flow | 1,057 | 808 | 773 | 394 | 636 | — | — | — | — | — |
| Levered free cash flow | 791 | 735 | 694 | 328 | 534 | — | — | — | — | — |